Published on 12/1/2020 in the Prospect News Structured Products Daily.
New Issue: UBS sells $100,000 trigger performance securities linked to AbbVie
By Kiku Steinfeld
Chicago, Dec. 1 – UBS AG, London Branch priced $100,000 of 0% trigger performance securities due Nov. 22, 2024 linked to the common stock of AbbVie Inc., according to a 424B2 filing with the Securities and Exchange Commission.
The payout at maturity will be par of $10 plus 176.069885% of any gain in the stock.
If the stock falls by up to 25%, the payout will be par.
Otherwise, investors will be fully exposed to any share price decline.
UBS Financial Services Inc. and UBS Investment Bank are the agents.
| Issuer: | UBS AG, London Branch
|
| Issue: | Trigger performance securities
|
| Underlying stock: | AbbVie Inc.
|
| Amount: | $100,000
|
| Maturity date: | Nov. 22, 2024
|
| Coupon: | 0%
|
| Price: | Par of $10
|
| Payout at maturity: | If stock gains, par plus 176.069885% of return; if stock falls by up to 25%, par; otherwise, full exposure to share price decline
|
| Initial price: | $99.67
|
| Trigger price: | $74.75, 75% of initial price
|
| Pricing date: | Nov. 19
|
| Settlement date: | Nov. 23
|
| Agents: | UBS Financial Services Inc. and UBS Investment Bank
|
| Fees: | 3%
|
| Cusip: | 90282H169
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
